Athena Gold Corp
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- $126.8M
- Website
- http://www.athira.com
- Introduction
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Athira Pharma
- Target Recruit Count
- 80
- Registration Number
- NCT06432647
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States
A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]-Fosgonimeton
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Athira Pharma
- Target Recruit Count
- 8
- Registration Number
- NCT05511558
- Locations
- 🇺🇸
Labcorp Clinical Research Unit, Madison, Wisconsin, United States
Safety, Tolerability, and Pharmacokinetics Study of ATH-1020
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Athira Pharma
- Target Recruit Count
- 32
- Registration Number
- NCT05169671
- Locations
- 🇺🇸
Biotrial, Inc., Newark, New Jersey, United States
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Athira Pharma
- Target Recruit Count
- 423
- Registration Number
- NCT04886063
- Locations
- 🇺🇸
University of Rochester-AD-CARE Program, Rochester, New York, United States
ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)
- Conditions
- Parkinson Disease DementiaDementia With Lewy Bodies
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Athira Pharma
- Target Recruit Count
- 28
- Registration Number
- NCT04831281
- Locations
- 🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸Premiere Research Institute, West Palm Beach, Florida, United States
🇺🇸QUEST Research Institute, Farmington Hills, Michigan, United States
A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
- Conditions
- Alzheimer DiseaseDementia of Alzheimer Type
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Athira Pharma
- Target Recruit Count
- 77
- Registration Number
- NCT04491006
- Locations
- 🇺🇸
Premiere Research Institute, West Palm Beach, Florida, United States
🇺🇸Neurological Associates of Albany, Albany, New York, United States
🇦🇺Australian Alzheimer's Research Organization, Nedlands, Western Australia, Australia
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
- Conditions
- Alzheimer DiseaseDementia of Alzheimer Type
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Athira Pharma
- Target Recruit Count
- 554
- Registration Number
- NCT04488419
- Locations
- 🇺🇸
University of Rochester-AD-CARE Program, Rochester, New York, United States
Safety, Tolerability, and Pharmacokinetics Study of NDX-1017
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Athira Pharma
- Target Recruit Count
- 88
- Registration Number
- NCT03298672
- Locations
- 🇺🇸
Biotrial Inc., Newark, New Jersey, United States